Skip to main content
Toggle navigation
Login
Search
Home
Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
P
P 447
PAIN ASSESSMENT CRITERIA (PAC) ANTICIPATE RECIST PROGRESSION AND CORRELATE WITH BLOOD LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 (GDF15) IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE)
Favorite
P 283
PALLIATIVE LATTICE RADIATION THERAPY IN SOFT TISSUE SARCOMA VERSUS CARCINOMA AND MELANOMA: OUTCOME COMPARISON
Favorite
P 405
PAN-RAS INHIBITION AS A NOVEL THERAPEUTIC STRATEGY FOR RAS-DRIVEN RHABDOMYOSARCOMA
Favorite
P 224
PAN-SARCOMA DATABASE (PSDB): AN UPDATE ON MIAMI'S COLLABORATIVE MULTI-USER DATA PIPELINE OF SARCOMA DATA USING REDCAP AND R CODING
Favorite
P 89
PATELLAR HEIGHT AND ITS INFLUENCE ON FUNCTIONAL OUTCOMES FOR MEGAPROSTHESES AROUND THE KNEE PERFORMED FOR ONCOLOGICAL INDICATIONS
Favorite
P 466
PATHOGENESIS AND THERAPEUTIC TARGETS IN KERATIN-POSITIVE GIANT CELL-RICH TUMOR
Favorite
P 145
PATHOLOGIC FRACTURE IN CHONDROSARCOMA OF LONG BONES: A RETROSPECTIVE COHORT STUDY
Favorite
P 217
PATIENT QUESTIONNAIRE EXPLORING THE PRE-SARCOMA DIAGNOSIS CHARACTERISTICS OF SARCOMA PATIENTS
Favorite
P 414
PATTERNS OF RELAPSE OF BORDERLINE AND MALIGNANT PHYLLODES TUMOUR- RESULTS FROM SARCOMA REFERENCE CENTRE (SRC)
Favorite
P 112
PEDIATRIC GIANT CELL TUMOR OF BONE
Favorite
P 384
PELVIC LOCATION PREDICTS WORSE OUTCOMES IN ALVEOLAR RHABDOMYOSARCOMA: UNDERUSE OF RADIOTHERAPY AND MISSED SURVIVAL BENEFIT
Favorite
P 98
PERCUTANEOUS STABILIZATION OF METASTATIC BONE LESIONS WITH A PHOTODYNAMIC INTRAMEDULLARY SYSTEM: EXPERIENCE FROM A 15-PATIENT CASE SERIES
Favorite
P 280
PERSONALIZED ULTRA-FRACTIONATED STEREOTACTIC ADAPTIVE RADIOTHERAPY (PULSAR) FOR ADULT AND PEDIATRIC SARCOMAS
Favorite
P 361
PEXIDARTINIB FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMORS: CLINICAL EXPERIENCE FROM FIVE CHINESE PATIENTS
Favorite
P 336
PEXIDARTINIB RISK EVALUATION AND MITIGATION STRATEGY PROGRAM: 5-YEAR RETROSPECTIVE HEPATIC SAFETY ASSESSMENT
Favorite
P 427
PHASE 1/2 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF PEEL-224 IN COMBINATION WITH VINCRISTINE AND TEMOZOLOMIDE IN ADOLESCENTS AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SARCOMAS
Favorite
P 433
PHASE I DOSE ESCALATION TRIAL OF STX-001, AN LNP SELF-REPLICATING MRNA EXPRESSING IL-12, IN PATIENTS WITH REFRACTORY TUMORS INCLUDING SARCOMAS
Favorite
P 406
PILOT STUDY: CAN A MULTIPARAMETRIC MRI-DERIVED MODEL OUTPERFORM RECIST PREDICTING PATHOLOGY RESPONSE IN RHABDOMYOSARCOMA?
Favorite
P 407
PIMICOTINIB IN TENOSYNOVIAL GIANT CELL TUMOR (TGCT): LONG-TERM EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 MANEUVER STUDY
Favorite
P 58
PLK1 AS A VULNERABLE TARGET OF BAP1-DRIVEN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS
Favorite
P 337
POOLED ANALYSIS OF TRABECTEDIN EFFICACY IN MYXOID/ROUND CELL LIPOSARCOMA FROM THREE PROSPECTIVE CLINICAL TRIALS
Favorite
P 338
POORLY DIFFERENTIATED SYNOVIAL SARCOMA: A HISTOLOGIC CHALLENGE OF AN AGGRESSIVE VARIANT
Favorite
P 339
POSTERIOR APPROACH FOR RADICAL RESECTION OF SACROCOCCYGEAL CHORDOMA: A SURGICAL PERSPECTIVE FROM A TERTIARY REFERRAL CENTER
Favorite
P 48
PRECLINICAL ACTIVITY OF MEK INHIBITION IN COMBINATION WITH CHEMOTHERAPY IN MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Favorite
P 40
PRECLINICAL EFFICACY OF A PH-SENSITIVE EXATECAN PEPTIDE-DRUG-CONJUGATE IN RHABDOMYOSARCOMA
Favorite
P 259
PRECLINICAL MODELING OF CHEMOTHERAPY RELEASE IDENTIFIES MITOCHONDRIAL ADAPTATIONS IN DOXORUBICIN TREATED OSTEOSARCOMA
Favorite
P 54
PRECLINICAL MODELS REVEALING MDM2-P53 INTERACTION AND DEPENDENCY FOR TUMOR CELL SURVIVAL IN WELL-DIFFERENTIATED (WD) AND DEDIFFERENTIATED (DD) LIPOSARCOMA (LPS).
Favorite
P 42
PRECLINICAL VALIDATION OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, AND EPIGENETIC SENSITIZATION STRATEGIES IN SOFT TISSUE SARCOMAS
Favorite
P 302
PREDICTORS AND OUTCOMES OF RECURRENT RETROPERITONEAL SARCOMA: A SINGLE-CENTER LATIN AMERICAN COHORT STUDY
Favorite
P 340
PREDICTORS OF LATE RECURRENCE AFTER SARCOMA SURGICAL RESECTION
Favorite
P 92
PRIMARY TUMOR SIZE AS AN INDEPENDENT PROGNOSTIC FACTOR IN OSTEOSARCOMA: PROPENSITY SCORE-MATCHED ANALYSIS DEMONSTRATES A CONTINUOUS DOSE-RESPONSE RELATIONSHIP
Favorite
P 385
PROGNOSTIC IMPACT OF PERIPHERAL BLOOD CELL RATIO VALUES IN PATIENTS WITH ADVANCED LEIOMYOSARCOMA: A REFERENCE CENTER EXPERIENCE.
Favorite
P 306
PROGNOSTIC NUTRITIONAL INDEX PREDICTS MAJOR POSTOPERATIVE COMPLICATIONS IN RETROPERITONEAL SARCOMA: RESULTS FROM THE LATAMSARC COHORT
Favorite
P 341
PROGNOSTIC RELEVANCE OF CYCLOPHOSPHAMIDE DOSE FOR HIGH-RISK RHABDOMYOSARCOMA IN ADULT PATIENTS TREATED WITH VAC THERAPY
Favorite
P 342
PROGNOSTIC RELEVANCE OF TUMOR LOCATION IN MYXOID LIPOSARCOMA
Favorite
P 343
PROGRESSION FREE SURVIVAL OF IMMUNE CHECKPOINT INHIBITORS IN THE FIRST-LINE TREATMENT OF METASTATIC SARCOMA: A SINGLE CENTER RETROSPECTIVE ANALYSIS.
Favorite
P 419
PROSPECTIVE REAL-WORLD STUDY OF LAROTRECTINIB (LARO) IN PATIENTS (PTS) WITH TRK FUSION SOLID TUMORS: INTERIM ANALYSIS OF ON-TRK
Favorite
P 296
PULMONARY CEMENT EMBOLISM ASSOCIATED WITH PERCUTANEOUS CEMENTOPLASTY FOR BONE METASTASIS: MECHANISMS AND PROTECTIVE FACTORS
Favorite
